Mudita Advisors LLP Buys 56,700 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Mudita Advisors LLP raised its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 19.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 354,801 shares of the company’s stock after acquiring an additional 56,700 shares during the period. Establishment Labs makes up about 8.4% of Mudita Advisors LLP’s portfolio, making the stock its 5th biggest holding. Mudita Advisors LLP owned approximately 1.27% of Establishment Labs worth $15,352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of the stock. Hood River Capital Management LLC acquired a new stake in shares of Establishment Labs during the 2nd quarter worth approximately $43,000. Nkcfo LLC bought a new position in shares of Establishment Labs in the 2nd quarter valued at $227,000. SG Americas Securities LLC acquired a new position in shares of Establishment Labs during the 2nd quarter worth $303,000. Black Swift Group LLC bought a new position in Establishment Labs in the third quarter valued at about $312,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in Establishment Labs during the second quarter worth about $373,000. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Stock Up 0.0 %

Shares of ESTA opened at $45.57 on Wednesday. The business has a 50-day moving average of $42.97 and a 200-day moving average of $45.05. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. Establishment Labs Holdings Inc. has a 1 year low of $22.05 and a 1 year high of $60.12.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. BTIG Research upped their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Citigroup boosted their price objective on Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Finally, Stephens reissued an “overweight” rating and set a $68.00 price target on shares of Establishment Labs in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.60.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.